[go: up one dir, main page]

AR026181A1 - Tratamiento de desordenes del sueno por medio del uso de desloratadina - Google Patents

Tratamiento de desordenes del sueno por medio del uso de desloratadina

Info

Publication number
AR026181A1
AR026181A1 ARP000105515A ARP000105515A AR026181A1 AR 026181 A1 AR026181 A1 AR 026181A1 AR P000105515 A ARP000105515 A AR P000105515A AR P000105515 A ARP000105515 A AR P000105515A AR 026181 A1 AR026181 A1 AR 026181A1
Authority
AR
Argentina
Prior art keywords
treatment
allergic rhinitis
disorders
desloratadina
sueno
Prior art date
Application number
ARP000105515A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23687734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR026181(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR026181A1 publication Critical patent/AR026181A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe el uso de desloratadina, sola o en combinacion con un descongestivo del pasaje aéreo superior, para la preparacion de un medicamento para eltratamiento y/o prevencion de desordenes del sueno en una persona que sufre de inflamacion alérgic a y/o congestion del pasaje aéreo superior asociadas conrinitis alérgica, incluyendo rinitis alérgica estacional o rinitis alérgica perenne, en donde el medicamento comprende una cantidad terapéuticamente efectivade desloratadina, sola o en combinaci on con otro activo tal como un descongestivo, por ejemplo, pseudoefedrina.
ARP000105515A 1999-10-22 2000-10-19 Tratamiento de desordenes del sueno por medio del uso de desloratadina AR026181A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/425,715 US6114346A (en) 1999-10-22 1999-10-22 Treating sleep disorders using desloratadine

Publications (1)

Publication Number Publication Date
AR026181A1 true AR026181A1 (es) 2003-01-29

Family

ID=23687734

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105515A AR026181A1 (es) 1999-10-22 2000-10-19 Tratamiento de desordenes del sueno por medio del uso de desloratadina

Country Status (16)

Country Link
US (2) US6114346A (es)
EP (1) EP1221953A1 (es)
JP (1) JP2003512429A (es)
CN (1) CN1379671A (es)
AR (1) AR026181A1 (es)
AU (1) AU779292B2 (es)
BR (1) BR0014912A (es)
CA (1) CA2386908A1 (es)
HK (1) HK1044119A1 (es)
HU (1) HUP0203529A3 (es)
MX (1) MXPA02003969A (es)
MY (1) MY120637A (es)
NO (1) NO20021845D0 (es)
PE (1) PE20010710A1 (es)
WO (1) WO2001030350A1 (es)
ZA (1) ZA200202542B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ284822B6 (cs) * 1993-06-14 1999-03-17 Janssen Pharmaceutica N. V. Tableta a způsob její výroby
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AU2276801A (en) * 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
MXPA02007558A (es) 2000-02-03 2002-12-13 Schering Corp Tratamiento de condiciones inflamatorias alergicas.
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
AU2002256967A1 (en) * 2000-10-30 2002-09-12 Schering Corporation Treating or reducing the risk of cardiovascular disease
US6651816B2 (en) * 2001-05-04 2003-11-25 Robert E. Weinstein Antihistamine/decongestant regimens for treating rhinitis
JP2004534820A (ja) * 2001-06-20 2004-11-18 シェーリング　コーポレイション 鼻うっ血および鼻閉塞の処置のための抗ヒスタミン薬
US20030236275A1 (en) * 2002-06-20 2003-12-25 Schering Corporation Treatment methods of nasal congestion and nasal obstruction
US6599913B1 (en) * 2001-06-29 2003-07-29 Schering Corporation Treating allergic and inflammatory conditions
US20030134844A1 (en) * 2001-10-31 2003-07-17 Pfizer Inc. Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
US6855735B2 (en) 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
JP4303925B2 (ja) * 2002-08-19 2009-07-29 篠田プラズマ株式会社 金属酸化膜の形成方法及びガス放電管の２次電子放出膜形成方法
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
JP2006509784A (ja) * 2002-12-02 2006-03-23 ラリャイン，オレゴ，アウグスト 中程度または重症のいびきを軽減させるかまたは治癒させるための医薬品
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
WO2005027853A2 (en) * 2003-09-19 2005-03-31 University Of Louisville Research Foundation Inc Method for treating snoring and sleep apnea with leukotriene antagonists
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
WO2007092333A1 (en) * 2006-02-03 2007-08-16 Hypnion, Inc. Use of olopatadine for treating sleep disorders
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
EP2029105A1 (en) * 2006-06-01 2009-03-04 Schering Corporation Phenylphrine pulsed release formulations and pharmaceutical compositions
MX2008015358A (es) * 2006-06-01 2009-03-06 Schering Corp Composiciones farmaceuticas para liberacion sostenida de fenilefrina.
PL2034970T3 (pl) * 2006-06-01 2012-12-31 Msd Consumer Care Inc Preparat farmaceutyczny o przedłużonym uwalnianiu zawierający fenylefrynę
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
CN101848706A (zh) * 2007-06-01 2010-09-29 先灵-普劳健康护理产品公司 包含底物和含活性成分和聚乙烯醇的包衣的药用组合物
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
WO2024144678A1 (en) * 2022-12-27 2024-07-04 Atatürk Üni̇versi̇tesi̇ Fi̇kri̇ Mülki̇yet Haklari Koordi̇natörlüğü Döner Sermaye İşletmesi̇ Orally disintegrating tablets (odt) formulations for the treatment of flu, common cold and allergic symptoms

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3940485A (en) * 1973-12-12 1976-02-24 Levinson Harold N Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds
US4008796A (en) * 1974-03-26 1977-02-22 General Concrete Of Canada Limited Control method for feeding items on a conveyor
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
WO1985003707A1 (en) * 1984-02-15 1985-08-29 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
US4783465A (en) * 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4731447A (en) * 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4804666A (en) * 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4777170A (en) * 1987-02-03 1988-10-11 Heinrich William A Method to prevent and treat the signs and symptoms of motion sickness
US4863931A (en) * 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
ZA914764B (en) * 1990-06-22 1992-03-25 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene,piperidylidene and piperazine compounds,compositions and methods of use
US5416091A (en) * 1990-12-18 1995-05-16 Burroughs Wellcome Co. Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
PT100502A (pt) * 1991-05-20 1993-08-31 Alza Corp Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
DE4442999A1 (de) * 1994-12-02 1996-06-05 Hexal Pharma Gmbh Pharmazeutische Zusammensetzung mit einem aktiven Loratidin-Metaboliten
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
TW522014B (en) * 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine

Also Published As

Publication number Publication date
NO20021845L (no) 2002-04-19
US6114346A (en) 2000-09-05
HK1044119A1 (zh) 2002-10-11
AU1573101A (en) 2001-05-08
CA2386908A1 (en) 2001-05-03
US6265414B1 (en) 2001-07-24
MY120637A (en) 2005-11-30
PE20010710A1 (es) 2001-07-12
NO20021845D0 (no) 2002-04-19
EP1221953A1 (en) 2002-07-17
AU779292B2 (en) 2005-01-13
MXPA02003969A (es) 2002-10-23
HUP0203529A3 (en) 2004-01-28
HUP0203529A2 (hu) 2003-02-28
JP2003512429A (ja) 2003-04-02
CN1379671A (zh) 2002-11-13
WO2001030350A1 (en) 2001-05-03
BR0014912A (pt) 2002-06-11
ZA200202542B (en) 2003-09-23

Similar Documents

Publication Publication Date Title
AR026181A1 (es) Tratamiento de desordenes del sueno por medio del uso de desloratadina
AR039130A2 (es) Metodo de administracion de un agente farmaceuticamente activo a un ojo humano
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
ATE277596T1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
ES2250416T3 (es) Estimulante de secreciohn de hormona de crecimiento.
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
ES2001391A6 (es) Procedimiento de obtencion de una composicion farmaceutica para el tratamiento de senos faciales y nasales, alergias y sintomas de resfriado.
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
MXPA05010402A (es) Oxido nitrico en el tratamiento de la inflamacion.
PT941085E (pt) Dispositivo para administracao electricamente assistida de agentes como a lidocaina e a epinefrina
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
AR028502A1 (es) Tratamiento de condiciones inflamatorias alérgicas
UY27416A1 (es) Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana
BR0010006A (pt) Utilização do saredutante e de seus sais farmaceuticamente aceitáveis para o preparo de medicamentos úteis no tratamento ou na prevenção do conjunto das perturbações do humor, das perturbações da adaptação ou das perturbações mistas ansiedade-depressão
AR027394A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR031122A1 (es) Uso de antagonistas de endotelina en la fabricacion de medicamentos utiles para el tratamiento del cancer y el dolor asociado con el mismo
BR0015938A (pt) Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa
ECSP003733A (es) Tratamiento de desordenes del sueño por medio del uso de desloratadina (caso alo1076)
BR0009704A (pt) Utilização do osanetant para a preparação de medicamentos úteis no tratamento das perturbações do humor
AR018825A1 (es) Antagonistas del receptor de bradiquinina no peptidica para uso en el tratamiento de trastornos y enfermedades oftalmicas
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación

Legal Events

Date Code Title Description
FB Suspension of granting procedure